Literature DB >> 3455646

Immunogenic effect of bacteriophage in patients subjected to phage therapy.

A Kucharewicz-Krukowska1, S Slopek.   

Abstract

Fifty seven cases of bacterial infections subjected to phage therapy were tested for a production of antibodies against the applied bacteriophages. Monoinfections confirmed in 40 patients were caused in majority of cases by pyogenic Staphylococci (29 cases) and rarely by Gram-negative bacteria: Klebsiella, Escherichia, Proteus and Pseudomonas (11 cases). Polyinfections caused by the above types of bacteria were recorded in 17 cases. The titer of neutralizing and hemagglutinating antibodies was determined before phage therapy, in the 10th day and in some cases in the 21st day of its course. The effect of natural and immune antibodies on the final result of therapy was analyzed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3455646

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  21 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Immunogenicity studies of proteins forming the T4 phage head surface.

Authors:  Krystyna Dąbrowska; Paulina Miernikiewicz; Agnieszka Piotrowicz; Katarzyna Hodyra; Barbara Owczarek; Dorota Lecion; Zuzanna Kaźmierczak; Andrey Letarov; Andrzej Górski
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

Review 4.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

5.  A phage protein that inhibits the bacterial ATPase required for type IV pilus assembly.

Authors:  In-Young Chung; Hye-Jeong Jang; Hee-Won Bae; You-Hee Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

Review 6.  Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.

Authors:  Justin D Glenn; Ellen M Mowry
Journal:  J Interferon Cytokine Res       Date:  2016-05-04       Impact factor: 2.607

7.  Phage neutralization by sera of patients receiving phage therapy.

Authors:  Marzanna Łusiak-Szelachowska; Maciej Zaczek; Beata Weber-Dąbrowska; Ryszard Międzybrodzki; Marlena Kłak; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Krzysztof Szufnarowski; Ewa Jończyk-Matysiak; Barbara Owczarek; Andrzej Górski
Journal:  Viral Immunol       Date:  2014-06-03       Impact factor: 2.257

8.  Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model.

Authors:  Archana Archana; Prem Shankar Patel; Rajesh Kumar; Gopal Nath
Journal:  Virusdisease       Date:  2021-03-10

9.  Ecological basis for rational phage therapy.

Authors:  A V Letarov; A K Golomidova; K K Tarasyan
Journal:  Acta Naturae       Date:  2010-04       Impact factor: 1.845

10.  Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus.

Authors:  Michał Zimecki; Jolanta Artym; Maja Kocieba; Beata Weber-Dabrowska; Jan Borysowski; Andrzej Górski
Journal:  BMC Microbiol       Date:  2009-08-17       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.